OTR Therapeutics and Zealand Pharma join forces to target metabolic diseases
The companies aim to expand treatment options for millions living with metabolic disorders
The companies aim to expand treatment options for millions living with metabolic disorders
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
While Merck can appeal, Halozyme said it expects the order to hold
VitiPure serves as essential solubilizers, emulsifiers, and bioavailability enhancers in drug formulations
Growing patent filings and tier-2 innovators reflect expanding national research base
The PCR-based test, delivered via Roche’s cobas liat system, allows results to be obtained during a patient consultation in GP practices and Emergency Rooms
The acquisitions merge DatCard and Sorna’s expertise in clinical data sharing with Avandra’s de-identified patient data aggregation platform
Subscribe To Our Newsletter & Stay Updated